Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto J Montero

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Journal of Medical Economics|February 11, 2014
Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88Vakaramoko Diaby, Georges Adunlin, Alberto J Montero
Cancer|July 29, 2020
Novel HER2-targeted therapies for HER2-positive metastatic breast cancerSiddharth Kunte, Jame Abraham, Alberto J Montero
Breast Cancer Research and Treatment|February 10, 2015
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective studyAlexandra Gomez, Alberto J Montero, Judith Hurley
Pharmacoeconomics - Open|September 6, 2018
Value Assessment Frameworks in the United States: A Call for Patient EngagementVakaramoko Diaby, Askal A Ali, Alberto J Montero
Gastrointestinal Cancer Research : GCR|March 6, 2009
Adjuvant and preoperative therapy for localized gastric cancerYixing Jiang, Alberto J Montero, Kevin F Staveley-O'Carroll
Breast Cancer Research and Treatment|December 28, 2011
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancerAlberto J Montero, Kiran Avancha, Stefan Glück, et al.
Breast Cancer Research and Treatment|June 12, 2012
The economic burden of metastatic breast cancer: a U.S. managed care perspectiveAlberto J Montero, Sara Eapen, Brian Gorin, et al.
Breast Cancer Research and Treatment|November 13, 2012
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancerGilberto Lopes, Stefan Glück, Kiran Avancha, et al.
JCO Oncology Practice|October 12, 2021
CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast CancerPriyanka M Reddy, James M Martin, Alberto J Montero
Seminars in Oncology|May 3, 2014
Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implicationsC Marcela Diaz-Montero, Jim Finke, Alberto J Montero
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Journal of Medical Economics|February 11, 2014
Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88Vakaramoko Diaby, Georges Adunlin, Alberto J Montero
Cancer|July 29, 2020
Novel HER2-targeted therapies for HER2-positive metastatic breast cancerSiddharth Kunte, Jame Abraham, Alberto J Montero
Breast Cancer Research and Treatment|February 10, 2015
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective studyAlexandra Gomez, Alberto J Montero, Judith Hurley
Pharmacoeconomics - Open|September 6, 2018
Value Assessment Frameworks in the United States: A Call for Patient EngagementVakaramoko Diaby, Askal A Ali, Alberto J Montero
Gastrointestinal Cancer Research : GCR|March 6, 2009
Adjuvant and preoperative therapy for localized gastric cancerYixing Jiang, Alberto J Montero, Kevin F Staveley-O'Carroll
Breast Cancer Research and Treatment|December 28, 2011
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancerAlberto J Montero, Kiran Avancha, Stefan Glück, et al.
Breast Cancer Research and Treatment|June 12, 2012
The economic burden of metastatic breast cancer: a U.S. managed care perspectiveAlberto J Montero, Sara Eapen, Brian Gorin, et al.
Breast Cancer Research and Treatment|November 13, 2012
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancerGilberto Lopes, Stefan Glück, Kiran Avancha, et al.
JCO Oncology Practice|October 12, 2021
CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast CancerPriyanka M Reddy, James M Martin, Alberto J Montero
Seminars in Oncology|May 3, 2014
Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implicationsC Marcela Diaz-Montero, Jim Finke, Alberto J Montero
Pageof 14